TLTorsten Lauritzen

Torsten Lauritzen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Torsten Lauritzen has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Variation in prescribing of lipid‐lowering medication in primary care is associated with incidence of cardiovascular disease and all‐cause mortality in people with screen‐detected diabetes: findings from the ADDITION‐Denmark trial

    by R. K. Simmons, A. H. Carlsen, S. J. Griffin, M. Charles, J. S. Christiansen, K. Borch‐Johnsen, A. Sandbæk, T. Lauritzen

    Aims: To examine variation between general practices in the prescription of lipid‐lowering treatment to people with screen‐detected Type 2 diabetes, and associations with practice and participant characteristics and risk of cardiovascular events and all‐cause mortality.Methods: Observational cohort analysis of data from 1533 people with screen‐detected Type 2 diabetes aged 40–69 years from the ADDITION‐Denmark study. One hundred and seventy‐four general practices were cluster randomized to receive: (1) routine diabetes care according to national guidelines (623 individuals), or (2) intensive multifactorial target‐driven management (910 individuals). Multivariable logistic regression was used to quantify the association between the proportion of individuals in each practice who redeemed prescriptions for lipid‐lowering medication in the two years following diabetes diagnosis and a composite cardiovascular disease (CVD) outcome, adjusting for age, sex, prevalent chronic disease, baseline CVD risk factors, smoking and lipid‐lowering medication, and follow‐up time.Results: The proportion of individuals treated with lipid‐lowering medication varied widely between practices (0–100%). There were 118 CVD events over 9431 person‐years of follow‐up. For the whole trial cohort, the risk of CVD was significantly higher in practices in the lowest compared with the highest quartile for prescribing lipid‐lowering medication [adjusted odds ratio (OR) 3.4, 95% confidence interval (CI) 1.6–7.3]. Similar trends were found for all‐cause mortality.Conclusions: More frequent prescription of lipid‐lowering treatment was associated with a lower incidence of CVD and all‐cause mortality. Improved understanding of factors underlying practice variation in prescribing may enable more frequent use of lipid‐lowering treatment. The results highlight the benefits of intensive treatment of people with screen‐detected diabetes (Clinical Trials Registry No; NCT 00237549).


    • 9 June 2014
      • Vol. 176  (12)

    [General practice plays a role in health check screening].

    by Torsten Lauritzen, Knut Borch-Johnsen, Annelli Sandbæk

    A Cochrane review has recently challenged the benefit of health checks. Included studies, screening procedures and treatments were however very heterogeneous and did not fulfil present days standards and most studies were done outside primary care. This review concentrates on research from health checks in Danish general practices focusing on early detection and treatment of risk factors for cardiovascular disease and diabetes. The authors recommend Danish general practitioners to offer opportunistic screening and treatment of people with diabetes and people at risk for cardiovascular disease. Future research questions are highlighted.

  • Open Access

    Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes

    by Zhulin Ma, Jens Sandahl Christiansen, Torben Laursen, Chunsen Wu, Torsten Lauritzen, Tina Parkner, Jan Frystyk

    Insulin aspart (IAsp) and its biphasic preparations BIAsp50 and BIAsp70 (containing 50% and 70% IAsp, respectively) have distinct glucose-lowering properties as compared to human insulin (HI). We investigated whether this affected the circulating IGF-system which depends on the hepatic insulin exposure. In a randomized, four-period crossover study, 19 patients with type 1 diabetes received identical doses (0.2 U/kg sc) of IAsp, BIAsp70, BIAsp50 and HI together with a standardized meal. Serum total IGF-I and IGFBP-1 to -3 were measured by immunoassays for nine hours post-prandially. Bioactive IGF was determined by an in-house, cell-based IGF-I receptor kinase activation (KIRA) assay. Despite marked differences in peripheral insulin concentrations and plasma glucose, the four insulin preparations resulted in parallel decreases in IGFBP-1 levels during the first 3 hours, and parallel increases during the last part of the study (3–9 hours). Thus, only minor significances were seen. Insulin aspart and human insulin resulted in a lower area under the curve (AUC) during the first 3 hours as compared to BIAsp70 (p = 0.009), and overall, human insulin resulted in a lower IGFBP-1 AUC than BIAsp70 (p = 0.025). Nevertheless, responses and AUCs of bioactive IGF were similar for all four insulin preparations. Changes in levels of bioactive IGF were inversely correlated to those of IGFBP-1, increasing during the first 3 hours, whereafter levels declined (-0.83 ≤ r ≤ -0.30; all p-values <0.05). Total IGF-I and IGFBP-3 remained stable during the 9 hours, whereas IGFBP-2 changed opposite of IGFBP-1, increasing after 3–4 hours whereafter levels gradually declined. The four insulin preparations resulted in similar profiles and AUCs of total IGF-I, IGFBP-2 and IGFBP-3. Despite distinct glucose-lowering properties, the tested insulin preparations had similar effects on IGF-I concentration and IGF bioactivity, IGFBP-2 and IGFBP-3 as compared to HI; only small differences in IGFBP-1 were seen and they did not affect bioactive IGF. Thus, insulin aspart containing preparation behaves as HI in regards to the circulating IGF-system. However, bioactive IGF appeared to be more sensitive to insulin exposure than total IGF-I. The physiological significance of this finding remains to be determined. NCT00888732


  • Open Access

    Studies of association of AGPAT6variants with type 2 diabetes and related metabolic phenotypes in 12,068 Danes

    by Lena Sønder Snogdal, Niels Grarup, Karina Banasik, Mette Wod, Torben Jørgensen, Daniel R Witte, Torsten Lauritzen, Aneta A Nielsen, Ivan Brandslund, Cramer Christensen, et al.

    Type 2 diabetes, obesity and insulin resistance are characterized by hypertriglyceridemia and ectopic accumulation of lipids in liver and skeletal muscle. AGPAT6 encodes a novel glycerol-3 phosphate acyltransferase, GPAT4, which catalyzes the first step in the de novo triglyceride synthesis. AGPAT6-deficient mice show lower weight and resistance to diet- and genetically induced obesity. Here, we examined whether common or low-frequency variants in AGPAT6 associate with type 2 diabetes or related metabolic traits in a Danish population.


  • Effects of human insulin and insulin aspart preparations on levels of IGFI, IGFBPs and IGFI bioactivity in patients with type 1 diabetes

    by Zhulin Ma, Jens Sandahl Christiansen, Torsten Lauritzen, Tina Parkner, Torben Laursen, Jan Frystyk

    Introduction: Type 1 diabetes (T1D) is characterized by primary insulin insufficiency and secondary disruption of GH–IGF–IGFBP axis. S.c. insulin therapy is necessary to normalize this axis. This study aimed to investigate whether the distinct insulin profiles obtained with insulin aspart and human insulin preparations, respectively, affect IGF1 concentration and bioactivity and IGFBP levels differently. Methods: In a randomized, four-period crossover study, 19 patients with T1D received identical doses (0.2 U/kg s.c.) of insulin aspart, BIAsp70, or BIAsp50 immediately before a standardized meal, or human insulin 30 min before meal. Serum total IGF1, bioactive IGF1 and IGFBP-1 to -3 were measured for 9 h postprandially. Results: After equipotent doses, IGFBP-1 levels decreased significantly during the first 3 h with all insulin treatments, but the AUC of IGFBP-1 was significantly higher in the BIAsp50 group (mean (range) 351, 312–396 μg h/l) as compared to insulin aspart (262, 233–294 μg h/l) and human insulin (256, 228–288 μg h/l, P=0.001). Human insulin showed lower AUC of IGFBP-1 than insulin aspart preparations during 0–3, 0–6, 6–9 and 0–9 h. During the first 6 h, the four insulin preparations resulted in similar profiles and AUCs of total IGF1, bioactive IGF1, IGFBP-2 and IGFBP-3. Whereas total IGF1 remained constant, bioactive IGF-I fell at the end of the study (6–9 h), concomitant with the increase in IGFBP-1. Conclusions: Despite distinct pharmacokinetic properties, the insulin aspart preparations had similar effects on IGF1 concentration and bioactivity, IGFBP-2 and IGFBP-3 as compared to those of human insulin, but differed in respect to IGFBP-1. Further, bioactive IGF-I appeared to be more sensitive to insulin exposure than total IGF1.

  • Open Access

    Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care

    by Nanna B Johansen, Anne-Louise S Hansen, Troels M Jensen, Annelotte Philipsen, Signe S Rasmussen, Marit E Jørgensen, Rebecca K Simmons, Torsten Lauritzen, Annelli Sandbæk, Daniel R Witte

    Background: Screening programmes for type 2 diabetes inevitably find more individuals at high risk for diabetes than people with undiagnosed prevalent disease. While well established guidelines for the treatment of diabetes exist, less is known about treatment or prevention strategies for individuals found at high risk following screening. In order to make better use of the opportunities for primary prevention of diabetes and its complications among this high risk group, it is important to quantify diabetes progression rates and to examine the development of early markers of cardiovascular disease and microvascular diabetic complications. We also require a better understanding of the mechanisms that underlie and drive early changes in cardiometabolic physiology. The ADDITION-PRO study was designed to address these issues among individuals at different levels of diabetes risk recruited from Danish primary care. Methods/Design: ADDITION-PRO is a population-based, longitudinal cohort study of individuals at high risk for diabetes. 16,136 eligible individuals were identified at high risk following participation in a stepwise screening programme in Danish general practice between 2001 and 2006. All individuals with impaired glucose regulation at screening, those who developed diabetes following screening, and a random sub-sample of those at lower levels of diabetes risk were invited to attend a follow-up health assessment in 2009–2011 (n = 4,188), of whom 2,082 (50%) attended. The health assessment included detailed measurement of anthropometry, body composition, biochemistry, physical activity and cardiovascular risk factors including aortic stiffness and central blood pressure. All ADDITION-PRO participants are being followed for incident cardiovascular disease and death. Discussion: The ADDITION-PRO study is designed to increase understanding of cardiovascular risk and its underlying mechanisms among individuals at high risk of diabetes. Key features of this study include (i) a carefully characterised cohort at different levels of diabetes risk; (ii) detailed measurement of cardiovascular and metabolic risk factors; (iii) objective measurement of physical activity behaviour; and (iv) long-term follow-up of hard clinical outcomes including mortality and cardiovascular disease. Results will inform policy recommendations concerning cardiovascular risk reduction and treatment among individuals at high risk for diabetes. The detailed phenotyping of this cohort will also allow a number of research questions concerning early changes in cardiometabolic physiology to be addressed.


  • Open Access

    The effect of FOXA2rs1209523 on glucose-related phenotypes and risk of type 2 diabetes in Danish individuals

    by Karina Banasik, Mette Hollensted, Ehm Andersson, Thomas Sparsø, Annelli Sandbæk, Torsten Lauritzen, Torben Jørgensen, Daniel R Witte, Oluf Pedersen, Torben Hansen

    Variations within the FOXA family have been studied for a putative contribution to the risk of type 2 diabetes (T2D), and recently the minor T-allele of FOXA2 rs1209523 was reported to associate with decreased fasting plasma glucose levels in a study using a weighted false discovery rate control procedure to enhance the statistical power of genome wide association studies in detecting associations between low-frequency variants and a given trait.


  • Open Access

    HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark

    by T. Lauritzen, A. Sandbaek, M. V. Skriver, K. Borch-Johnsen

    The measurement of HbA1c is suggested as a diagnostic test for diabetes. Screening for diabetes also identifies individuals with elevated cardiovascular risk but who are free of diabetes. This study aims to assess whether screening by HbA1c or glucose measures alone, or in combination with a cardiovascular risk assessment, identifies people who may benefit from preventive interventions, i.e. people with screen detected diabetes and people belonging to groups with excess mortality, during a median follow-up of 7 years. A population-based, stepwise high-risk screening programme was performed in 193 family practices from 2001 to 2006. Individuals aged between 40 and 69 years (N = 163,185) were sent a diabetes risk questionnaire. Of these, 20,916 people at risk of diabetes were stratified by glucose measures (normal glucose tolerance [NGT], impaired fasting glucose [IFG], impaired glucose tolerance [IGT] and diabetes), HbA1c (1c ≥ 6.0% identified 96.7% (95% CI 96.3–97.0%), compared with 97.6% (95%CI 97.2–97.9%) in combination with glucose measures. Glucose measures or HbA1c alone identified 26.1% (95% CI 25.2–27.0%) and 19.8% (95% CI 19.0–20.6%), respectively. In a population-based high risk screening programme in primary care, HbA1c ≥ 6.0% combined with an elevated cardiovascular risk assessment (SCORE ≥ 5) can feasibly be used to identify those who may benefit from preventive lifestyle intervention and/or polypharmacy. ClinicalTrials.gov NCT 00237549. The study received unrestricted grants from Novo Nordisk, Novo Nordisk Scandinavia, Astra Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, Servier Denmark and HemoCue Denmark.


  • Open Access

    The minor C-allele of rs2014355 in ACADSis associated with reduced insulin release following an oral glucose load

    by Malene Hornbak, Karina Banasik, Johanne M Justesen, Nikolaj T Krarup, Camilla H Sandholt, Åsa Andersson, Annelli Sandbæk, Torsten Lauritzen, Charlotta Pisinger, Daniel R Witte, et al.

    Background: A genome-wide association study (GWAS) using metabolite concentrations as proxies for enzymatic activity, suggested that two variants: rs2014355 in the gene encoding short-chain acyl-coenzyme A dehydrogenase (ACADS) and rs11161510 in the gene encoding medium-chain acyl-coenzyme A dehydrogenase (ACADM) impair fatty acid β-oxidation. Chronic exposure to fatty acids due to an impaired β-oxidation may down-regulate the glucose-stimulated insulin release and result in an increased risk of type 2 diabetes (T2D). We aimed to investigate whether the two variants associate with altered insulin release following an oral glucose load or with T2D. Methods: The variants were genotyped using KASPar® PCR SNP genotyping system and investigated for associations with estimates of insulin release and insulin sensitivity following an oral glucose tolerance test (OGTT) in a random sample of middle-aged Danish individuals (n ACADS = 4,324; n ACADM = 4,337). The T2D-case-control study involved a total of ~8,300 Danish individuals (n ACADS = 8,313; n ACADM = 8,344). Results: In glucose-tolerant individuals the minor C-allele of rs2014355 of ACADS associated with reduced measures of serum insulin at 30 min following an oral glucose load (per allele effect (β) = -3.8% (-6.3%;-1.3%), P = 0.003), reduced incremental area under the insulin curve (β = -3.6% (-6.3%;-0.9%), P = 0.009), reduced acute insulin response (β = -2.2% (-4.2%;0.2%), P = 0.03), and with increased insulin sensitivity ISIMatsuda (β = 2.9% (0.5%;5.2%), P = 0.02). The C-allele did not associate with two other measures of insulin sensitivity or with a derived disposition index. The C-allele was not associated with T2D in the case-control analysis (OR 1.07, 95% CI 0.96-1.18, P = 0.21). rs11161510 of ACADM did not associate with any indices of glucose-stimulated insulin release or with T2D. Conclusions: In glucose-tolerant individuals the minor C-allele of rs2014355 of ACADS was associated with reduced measures of glucose-stimulated insulin release during an OGTT, a finding which in part may be mediated through an impaired β-oxidation of fatty acids.